HIV Science Races Ahead As Funding Crisis Threatens to Widen Access Gap

Scientific innovation in the fight against HIV is accelerating, yielding highly promising prevention and treatment tools, including a twice-yearly injectable medication and a potential once-weekly oral treatment. For over two decades, these scientific breakthroughs, supported by international financing, have transformed HIV from a fatal diagnosis into a manageable chronic condition for millions globally.

However, this progress is threatened by funding uncertainties. New evidence indicates that disruptions to the US President's Emergency Plan for AIDS Relief (PEPFAR) are already curtailing vital HIV services in countries heavily reliant on the program. Beatriz Grinsztejn, President of the International AIDS Society, stated, "Science is moving fast, giving us more powerful HIV prevention and treatment tools. But these advances cannot save lives if they never reach the people who need them." She stressed the need for "robust, stable financing and steadfast political commitment."

The impact of these funding disruptions, which began in January 2025 following a US executive order pausing foreign assistance for review, is significant. A global survey of 166 implementing partners across 46 countries revealed that more than half had lost at least one funding award. Consequently, 77% of partners were forced to restrict activities due to additional US policy requirements. This has led to the closure of 1,714 HIV service sites, including public health facilities and community centers.

Local organizations serving communities most vulnerable to HIV have been disproportionately affected. Several implementing partners reported ceasing services for key populations at higher risk of infection. Others noted shortages of essential supplies like condoms, laboratory materials, pre-exposure prophylaxis (PrEP) medications, and antiretroviral drugs. Some organizations have reduced program scope or discontinued activities to secure available funding, jeopardizing the continuity of care for those living with HIV.

“

Science is moving fast, giving us more powerful HIV prevention and treatment tools. But these advances cannot save lives if they never reach the people who need them. That requires robust, stable financing and steadfast political commitment.